Novo Nordisk today announced that the European Commission has approved the rapid-acting insulin NovoRapid® (insulin aspart) for treatment of diabetes in the elderly and in people with renal or hepatic impairment. 
Nearly three times as many patients receiving Selzentry, in addition to an optimized background regimen, achieved undetectable levels of HIV virus compared with those receiving an optimized regimen alone, according to 48 week data presented today in late-breaking sessions at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting. This newly approved CCR5 antagonist - the first new class of oral HIV medicines introduced in more than ten years - is now available throughout the U.S. 
AstraZeneca PLC, rated A1 (stable) by Moody's and AA- (stable) by Standard & Poor's, priced a successful debut eurobond transaction (the "Bonds") issuing a total of EUR750 million. The proceeds of the issue will be used for general corporate purposes and to repay a portion of the outstanding US commercial paper taken on in connection with the acquisition of MedImmune. 
Forest Laboratories (NYSE: FRX) announced today that single doses of inhaled aclidinium produced a significant bronchodilatory response in 17 patients with COPD according to results of a phase IIa trial presented today at the European Respiratory Society (ERS) Annual Congress in Stockholm.(1) 
H. Lundbeck A/S and Takeda Pharmaceutical Company Limited announced a strategic alliance for the exclusive co-development and co-commercialization in the United States and Japan of several compounds in Lundbeckâ's pipeline for the treatment of mood and anxiety disorders. 
The European Respiratory Society (ERS) is pleased to announce that Dr Morten Dahl, Herlev University Hospital in Copenhagen, Denmark and Simonetta Baraldo, Padova, Italy, are this year's winners of the Society's annual award for research in the field of Chronic Obstructive Pulmonary Disease (COPD). 
The European Commission, on 25 June 2007, granted marketing authorisation for INVEGA® (paliperidone prolonged-release tablets), a new atypical antipsychotic medication for the treatment of schizophrenia. This once daily medication is specifically designed to deliver paliperidone - the active ingredient in INVEGA® - through the innovative osmotic delivery system (OROS®) resulting in strong efficacy, a proven safety and tolerability profile and improved patient functioning. 